Navigation Links
Valeant Pharmaceuticals Completes Acquisition of Dermik
Date:12/19/2011

MISSISSAUGA, Ontario, Dec. 19, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that effective December 16, 2011, the company completed its previously announced acquisition of Dermik, a dermatology unit of Sanofi (EURONEXT: SAN and NYSE: SNY).

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

 


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Valeant Announces Successful Results From Phase III Onychomycosis Trials
2. Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc.
3. Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik
4. Valeant Pharmaceuticals to Syndicate Incremental Term Loans
5. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
6. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
7. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
8. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
9. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
10. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
11. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... LEXINGTON, Mass. , March 27, 2017   Pulmatrix, ... innovative inhaled therapies to address serious pulmonary diseases, today announced ... allergic fungal disease, cystic fibrosis and asthma to its ... Richard B. Moss , MD, ... former Director of the Cystic Fibrosis Center at Stanford University, ...
(Date:3/27/2017)... March 27, 2017 The global ... USD 16.0 billion by 2025, according to a new ... of chronic diseases is anticipated to be responsible for ... thereby widens the scope for growth during the forecast ... population, which is highly susceptible to chronic diseases, is ...
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of ... were things that his parents and teachers had asked of him that he had neglected ... going to defy the Almighty Creator. There were some who would have felt themselves to ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... White Plains, NY (PRWEB) , ... March 27, 2017 , ... ... honoring Root Canal Awareness Week by teaching their patients about the key role this ... canal therapy from an experienced endodontist. To better serve those who need a ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):